PRLX 93936

DRUG2 trials

Sponsors

Prolexys Pharmaceuticals

Conditions

CancerMultiple Myeloma

Phase 1

Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors

CompletedNCT00528047

Prolexys PharmaceuticalsCancer

Start: 2007-08-31End: 2011-11-30Updated: 2012-01-05

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

Prolexys PharmaceuticalsMultiple Myeloma

Start: 2012-03-31End: 2014-09-30Target: 40Updated: 2013-06-04